DNMT3A R882 mutation, particularly when accompanied by FLT3-ITD positivity, had a significant prognostic impact on survival and relapse rates in patients with NK-AML after allogeneic hematopoietic cell transplantation.
In contrast, non–R882 DNMT3A mutations did not influence transplantation outcome.
No differences in overall survival, event-free survival, or relapse incidence were observed in patients with TET2 mutation or IDH1/2 mutation after allogeneic hematopoietic cell transplantation.